Open AccessCOVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial
Author(s) -
Bruno Martins Tomazini,
Israel Silva Maia,
Flávia Regina Bueno,
Maria Vitoria Aparecida Oliveira Silva,
Franca Pellison Baldassare,
Eduardo Leite Vieira Costa,
Ricardo Antonio Bonifácio Moura,
Michele Ouriques Honorato,
André Nathan Costa,
Alexandre Biasi Cavalcanti,
Régis Goulart Rosa,
Álvaro Avezum,
Viviane Cordeiro Veiga,
Renato D. Lópes,
Lucas Petri Damiani,
Flávia Ribeiro Machado,
Otávio Berwanger,
Luciano César Pontes Azevedo
Publication year - 2020
Publication title -
revista brasileira de terapia intensiva
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.431
H-Index - 19
eISSN - 1982-4335
pISSN - 0103-507X
DOI - 10.5935/0103-507x.20200063
Subject(s) - medicine , ards , covid-19 , randomized controlled trial , pneumonia , dexamethasone , coronavirus infections , betacoronavirus , pandemic , acute respiratory distress , intensive care medicine , virology , lung , outbreak , infectious disease (medical specialty) , disease
The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV-2 infection (coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop acute respiratory distress syndrome. Several clinical trials evaluated the role of corticosteroids in non-COVID-19 acute respiratory distress syndrome with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe acute respiratory distress syndrome due to confirmed or probable COVID-19.